30 related articles for article (PubMed ID: 12009951)
1. Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours.
de Visser M; Bernard HF; Erion JL; Schmidt MA; Srinivasan A; Waser B; Reubi JC; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1228-38. PubMed ID: 17287960
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Mouse and Human Serum Stability of a Heterobivalent Dual-Target Probe That Has Strong Affinity to Gastrin-Releasing Peptide and Neuropeptide Y1 Receptors on Tumor Cells.
Ghosh A; Raju N; Tweedle M; Kumar K
Cancer Biother Radiopharm; 2017 Feb; 32(1):24-32. PubMed ID: 28186846
[TBL] [Abstract][Full Text] [Related]
3. A New, Second Generation Trithiol Bifunctional Chelate for
Najafi Khosroshahi F; Feng Y; Ma L; Manring S; Rold TL; Gallazzi FA; Kelley SP; Embree MF; Hennkens HM; Hoffman TJ; Jurisson SS
Bioconjug Chem; 2021 Jul; 32(7):1364-1373. PubMed ID: 33423467
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of radioiodinated vesamicol analogs for sigma receptor imaging in tumor and radionuclide receptor therapy.
Ogawa K; Shiba K; Akhter N; Yoshimoto M; Washiyama K; Kinuya S; Kawai K; Mori H
Cancer Sci; 2009 Nov; 100(11):2188-92. PubMed ID: 19659515
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart.
Oroujeni M; Abouzayed A; Lundmark F; Mitran B; Orlova A; Tolmachev V; Rosenström U
Pharmaceutics; 2019 Aug; 11(8):. PubMed ID: 31382362
[TBL] [Abstract][Full Text] [Related]
6. HYNIC and DOMA conjugated radiolabeled bombesin analogs as receptor-targeted probes for scintigraphic detection of breast tumor.
De K; Mukherjee D; Sinha S; Ganguly S
EJNMMI Res; 2019 Mar; 9(1):25. PubMed ID: 30887136
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and preliminary evaluation of a new (99m)tc labeled substance p analogue as a potential tumor imaging agent.
Mozaffari S; Erfani M; Beiki D; Johari Daha F; Kobarfard F; Balalaie S; Fallahi B
Iran J Pharm Res; 2015; 14(1):97-110. PubMed ID: 25561916
[TBL] [Abstract][Full Text] [Related]
8. PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues.
Däpp S; Müller C; Garayoa EG; Bläuenstein P; Maes V; Brans L; Tourwé DA; Schibli R
EJNMMI Res; 2012 Jun; 2(1):24. PubMed ID: 22681935
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cells.
Martin AL; Hickey JL; Ablack AL; Lewis JD; Luyt LG; Gillies ER
J Nanopart Res; 2009 Jun; 12(5):1599-1608. PubMed ID: 22328862
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeled nano-peptides show specificity for an animal model of human PC3 prostate cancer cells.
Faintuch BL; Núñez GE; Teodoro R; Moro AM; Mengatti J
Clinics (Sao Paulo); 2011; 66(2):327-36. PubMed ID: 21484054
[TBL] [Abstract][Full Text] [Related]
11. Bombesin receptor-mediated imaging and cytotoxicity: review and current status.
Sancho V; Di Florio A; Moody TW; Jensen RT
Curr Drug Deliv; 2011 Jan; 8(1):79-134. PubMed ID: 21034419
[TBL] [Abstract][Full Text] [Related]
12. 99mTc(CO)3-DTMA bombesin conjugates having high affinity for the GRP receptor.
Lane SR; Veerendra B; Rold TL; Sieckman GL; Hoffman TJ; Jurisson SS; Smith CJ
Nucl Med Biol; 2008 Apr; 35(3):263-72. PubMed ID: 18355681
[TBL] [Abstract][Full Text] [Related]
13. Targeting prostate cancer with radiolabelled bombesins.
Maina T; Nock B; Mather S
Cancer Imaging; 2006 Nov; 6(1):153-7. PubMed ID: 17098646
[TBL] [Abstract][Full Text] [Related]
14. A 99mTc(I)-postlabeled high affinity bombesin analogue as a potential tumor imaging agent.
La Bella R; Garcia-Garayoa E; Bahler M; Bläuenstein P; Schibli R; Conrath P; Tourwé D; Schubiger PA
Bioconjug Chem; 2002; 13(3):599-604. PubMed ID: 12009951
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
[TBL] [Abstract][Full Text] [Related]
16. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
[TBL] [Abstract][Full Text] [Related]
17. Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors.
Schweinsberg C; Maes V; Brans L; Bläuenstein P; Tourwé DA; Schubiger PA; Schibli R; García Garayoa E
Bioconjug Chem; 2008 Dec; 19(12):2432-9. PubMed ID: 19053304
[TBL] [Abstract][Full Text] [Related]
18. Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours.
Ferro-Flores G; Arteaga de Murphy C; Rodriguez-Cortés J; Pedraza-López M; Ramírez-Iglesias MT
Nucl Med Commun; 2006 Apr; 27(4):371-6. PubMed ID: 16531924
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
